A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Non-Biologic Lupus Standard of Care

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Systemic Lupus Erythematosus
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Ability of the participant to understand the purpose and risks of the study, to provide informed consent, and to authorize the use of confidential health information in accordance with national and local privacy regulations.
    2. Participant must be = 18 years of age at the time of signing the ICF.
    3. All women of childbearing potential must practice effective contraception during the study treatment period and for 90 days after their last dose of study treatment.
    4. Participant must be diagnosed with SLE at least 24 weeks prior to Screening.

You may not be eligible for this study if the following are true:

    1. History of or positive test result for HIV.
    2. Current hepatitis C infection. to participate in the study.
    3. Current hepatitis B infection.
    4. History of chronic, recurrent (3 or more of the same type of infection in a 52-week period), or recent serious infection (e.g., pneumonia, septicemia), including viral infections, as determined by the Investigator, or requiring anti-infective treatment within the 12 weeks prior to Screening.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.